Infarmed approves 14 applications for use of innovative drug for cystic fibrosis treatment

By TPN/Lusa, in Health & Environment, News · 10-03-2021 15:00:00 · 0 Comments

Infarmed has approved 14 requests for Special Use Authorisation (SUE) of Kaftrio, for the treatment of cystic fibrosis, including six from the University Hospital Centre of Lisbon North (CHULN), a source at the agency confirmed to Lusa on 9 March.

Among the approvals is the request for use of the innovative drug in the patient Constança Bradell, who complained about the delay in approval in Portugal of the treatment for cystic fibrosis, a genetic, hereditary and rare disease.

The clinical director of the CHULN said that the innovative treatment could soon reach five more patients from that hospital centre, which includes the Santa Maria Hospital and Pulido Valente Hospital.



Related articles


Comments:

Be the first to comment on this article
Interactive Topics, send us your comments/opinion on this article.

Please note that The Portugal News may use selected comments in the printed edition of the newspaper.